Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $41.7778.

A number of research analysts have commented on the stock. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th.

Insider Buying and Selling

In other news, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. The trade was a 34.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the sale, the insider owned 80,760 shares in the company, valued at $2,825,792.40. This represents a 64.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 465,931 shares of company stock valued at $16,332,989 over the last quarter. 0.54% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Victrix Investment Advisors boosted its stake in shares of Teva Pharmaceutical Industries by 9.5% in the second quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock valued at $266,000 after purchasing an additional 681 shares during the period. Assenagon Asset Management S.A. increased its stake in Teva Pharmaceutical Industries by 128.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock worth $103,538,000 after buying an additional 1,716,315 shares during the period. GAMMA Investing LLC increased its stake in Teva Pharmaceutical Industries by 19.6% during the 2nd quarter. GAMMA Investing LLC now owns 11,361 shares of the company’s stock worth $385,000 after buying an additional 1,859 shares during the period. Versant Capital Management Inc lifted its holdings in Teva Pharmaceutical Industries by 15.8% during the 2nd quarter. Versant Capital Management Inc now owns 10,265 shares of the company’s stock worth $348,000 after buying an additional 1,399 shares in the last quarter. Finally, CX Institutional acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $54,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $31.36 on Friday. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The business’s fifty day simple moving average is $33.57 and its 200-day simple moving average is $32.70. The firm has a market cap of $36.05 billion, a PE ratio of 23.58, a price-to-earnings-growth ratio of 3.27 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities analysts forecast that Teva Pharmaceutical Industries will post 1.99 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.